| Entries |
| Document | Title | Date |
|---|
| 20080207582 | Substituted Porphyrins - A series of ortho isomers of meso tetrakis N-alkylpyridylporphyrins (alkyl being methyl, ethyl, n-propyl, n-butyl, n-hexyl, and n-octyl) and their Mn(III) complexes were synthesized and characterized by elemental analysis, uv/vis spectroscopy, electrospray ionization mass spectrometry and electrochemistry. An increase in the number of carbon atoms in the alkyl chains from 1 to 8 is accompanied by an increase in: (a) lipophilicity measured by the chromatographic retention factor, R | 08-28-2008 |
| 20080269184 | Niosome Having Metal Porphyrin Complex Embedded Therein, Process For Producing The Same And Drug With The Use Thereof - A niosome having a metalloporphyrin complex embedded therein comprising a cationized metalloporphyrin complex and a niosome-forming substance. The niosome having a metalloporphyrin complex embedded therein has an SOD activity, can interact with superoxide anionic radicals (O | 10-30-2008 |
| 20080269185 | Methods Of Treating Oral Mucositis - Methods and kits for treating oral mucositis are disclosed. The treatment comprises administering to a patient in need thereof a Reactive Oxygen Species scavenger in a pharmaceutically acceptable formulation. | 10-30-2008 |
| 20080269186 | Functional Nanomaterials With Antibacterial and Antiviral Activity - The present invention relates to nanomaterials comprised of metal oxides associated with cationic metals having antibacterial activity. In particular, the present invention relates to nanocrystalline compounds of formula (I): AOx- (L-Men+) i, (I) where AOx represents the metal oxide or metalloid oxide, with x=1 or 2; Me11“1” is a metal ion having antibacterial activity, with n=1 or 2; L is a bifunctional molecule, either organic or organometallic, capable of binding simultaneously with the metal oxide or metalloid oxide and the metal ion Men+; and i represents the number of L-Men+groups bound to a AOx nanoparticle. | 10-30-2008 |
| 20080275019 | METAL COMPLEX PROTEIN KINASE INHIBITORS - This inventive subject matter relates to novel metal complex protein kinases inhibitors, methods for making such compounds, and methods for using such compounds for treating diseases and disorders mediated by kinase activity. | 11-06-2008 |
| 20080318917 | POLYETHYLENE GLYCOLATED SUPEROXIDE DISMUTASE MIMETICS - Compounds and methods for utilizing compounds comprising a superoxide dismutase mimetic covalently linked to polyethylene glycol. Methods are also provided for preparing a superoxide dismutase mimetic covalently linked to a polyethylene glycol, the methods comprising reacting an activated polyethylene glycol with a superoxide, dismutase mimetic, or alternatively, reacting a superoxide dismutase mimetic with an activated polyethylene glycol. A method is also provided for preventing or treating a disease or disorder in which superoxide anions are implicated, comprising administering to a subject in need thereof, a therapeutically effective amount of a compound comprising a superoxide dismutase mimetic covalently linked to a polyethylene glycol. Methods of determining the safety and efficacy of the compounds ere also provided. Methods for determining the safety and efficacy can include methods in lab animals and humans. | 12-25-2008 |
| 20090023700 | NEUROPROTECTIVE TREATMENTS - The present invention provides a therapeutic method for treating traumatic neural injury or a degenerative disorder in a mammal by administering a neuroprotective compound, wherein the neuroprotective compound is a peroxovanadium compound, a peroxovandium derivative, or a compound with inhibitory activity of protein tyrosine phosphatases. | 01-22-2009 |
| 20090036416 | Novel CXCR4 Antagonist and Use Thereof - A novel non-peptide CXCR4 antagonist has a low molecular-weight and uses various aromatic compounds, each containing a dipicolylamine-zinc complex. This CXCR4 antagonist finds use, e.g., as an anti-HIV agent, a metastasis inhibitor for a malignant tumor, and a chronic rheumatoid arthritis treatment and/or prevention agent. | 02-05-2009 |
| 20090036417 | COCHLEATES WITHOUT METAL CATIONS AS BRIDGING AGENTS - This invention provides a cochleate and nano-cochleate systems wherein the agents bridging lipid bilayer are organic multi-valent cations. This invention also provides a method for preparing the cochleate system comprising direct cochleation and hydrogel-isolated procedure. The preparation method comprises using the charge ration between the bridging agents and lipids to control the particle sizes. This cochleate or nano-cochleate system may be used for microencapsulation and delivery of therapeutics wherein the therapeutic agents are loaded in the cochleate structure as the bridging agents between lipid bilayers. Finally, this invention provides other uses of these new cochleate and nano- cochleate systems. | 02-05-2009 |
| 20090099150 | Methotrexate Combinations For Treating Inflammatory Diseases - Compounds, methods and kits for treating inflammatory diseases are disclosed. The treatment comprises administering to a patient in need thereof, methotrexate and a Reactive Oxygen Species scavenger in a pharmaceutically acceptable formulation. | 04-16-2009 |
| 20090131392 | PHTALOCYANINE DERIVATIVES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE - Phthalocyanine derivatives are described having photosensitising characteristics and high solubility in water, useful for photodynamic treatment of bacterial infections, in particular infections generated by Gram-negative bacteria. | 05-21-2009 |
| 20090131393 | Process for Preparing Chlorides of Phthalocyanine Derivatives Comprising at Least a Quaternary Ammonium Group - A process is described for preparing chlorides of phthalocyanine derivatives comprising at least a quaternary ammonium group, products useful as photosensitising agents in photodynamic therapy. | 05-21-2009 |
| 20090149436 | CASPASE INHIBITOR - The present invention provides a caspase inhibitor containing a cobalt porphyrin complex compound or cobalt choline complex compound as an active ingredient. The caspase inhibitor of the present invention can strongly and specifically inhibit the caspase activity. In addition, the caspase inhibitor/cobalt porphyrin complex compound or cobalt choline complex compound of the present invention is useful as a pharmaceutical agent for the prophylaxis or treatment of various diseases relating to apoptosis. | 06-11-2009 |
| 20090186864 | RUTHENIUM (II) COMPOUNDS - A ruthenium (II) compound of formula (I): | 07-23-2009 |
| 20090197853 | METHODS AND COMPOSITIONS OF TREATING CANCER - The present disclosure involves the use of metal-containing texaphyrins and zinc (II) reagents for the treatment of tumors, atheromas and other neoplastic tissue. The present application demonstrates increased oxidative stress, alterations in zinc homeostasis, cell cycle arrest, and apoptosis of cancer cells in the presence of texaphyrins and/or zinc. One aspect is to monitor oxidative stress and/or alterations in zinc homeostasis in target cells prior to and/or after treatment with metal-containing texaphyrins and/or zinc (II) reagents as a predictor for treatment efficacy. The present disclosure provides molecular basis for the cell cycle arrest and apoptosis on cancer cells in the presence of texaphyrins and zinc. Another aspect is to monitor different genes involved in response to treatment with texaphyrins and zinc prior to and/or after treatment as predictors for treatment efficacy. | 08-06-2009 |
| 20090209508 | Compounds for Photochemotherapy - Enzyme-activatable photosensitizing polymer conjugates are disclosed for photochemotherapeutic treatment of human diseases and disorders, bacteriologic or virologic indications, cosmetic applications and other pathologic situations. These polymer conjugates may comprise a polymer carrier, a photosensitizer, a quencher, a targeting molecule and/or a biocompatibilizing unit. These macromolecular conjugates may be designed to guide to the target tissue a photosensitizing agent in an inactive, non-phototoxic form. However, upon entering the target environment, in which certain enzymes are presently active, the conjugate may release its photosensitizers in its fully active form, resulting in a highly localized activation of the photoactive agent. Also described here are methods, compositions and kits for the preparation and testing of such photochemotherapcutic conjugates. | 08-20-2009 |
| 20090253668 | Hair Loss Prevention by Natural Amino Acid and Peptide Complexes - This invention relates to certain skin and hair care agents of formula (I), derived from natural amino acids and peptides. These agents provide multi-functional treatment of enzyme-related skin, hair and scalp problems, for example, hair aging including premature hair loss and hair graying; male pattern baldness; hair loss from dandruff; alopecia; split ends, acne, darkened skin, dark circles around eyes, stretch marks, wrinkles and fine lines, loss of collagen, loss of skin pliability and combinations thereof: | 10-08-2009 |
| 20090275547 | METAL COMPLEX PHOSPHATIDYL-INOSITOL-3-KINASE INHIBITORS - Provided are novel organometallic compounds that inhibit PI3K lipid kinase and phospho-AKT in human melanoma cells, and also inhibit the migration of melanoma cells. The present invention is also directed to methods for inhibiting cancer cell proliferation, migration or both comprising contacting a cancer cell with a disclosed organometallic kinase inhibitor. Also disclosed are methods for treating a kinase-affected disease or condition comprising administering to a subject in need thereof a therapeutically effective amount of a disclosed organometallic kinase inhibitor. | 11-05-2009 |
| 20090275548 | COMPOUNDS AND METHODS FOR ACTIVATED THERAPY - Provided herein are compounds for detection, diagnosis and treatment of target tissues or target compositions, including hyperproliferative tissues such as tumors, using sonodynamic and/or photodynamic methods. In particular, photosensitizer and/or sonosensitizer compounds that collect in hyperproliferative tissue are provided. | 11-05-2009 |
| 20090291934 | Method for decomposing an allergen - An allergen decomposer which contains as an active ingredient a derivative of metal phthalocyanine represented by the following formula (I) | 11-26-2009 |
| 20090325922 | TURFGRASS FUNGICIDE FORMULATION WITH PIGMENT - Oil-in-water fungicidal formulations are prepared having pigment dispersed therein, the pigment being stable within the oil-in-water emulsion as a result of the addition of suitable silicone surfactants and suitable emulsifiers. The formulations can be prepared either as a 2-pack formulation or as a single formulation. In the case of the single formulation polyethylene glycol is also added. In either case, the formulations show a synergistic effect through the addition of the pigment, the resulting formulations having an increased efficacy. Further, the formulations show a synergistic effect when mixed with conventional chemical fungicides, both being added in reduced amounts compared to recommended rates. | 12-31-2009 |
| 20100093688 | Porphyrin catalysts and methods of use thereof - This invention provides a novel class of substituted macrocyclic porphyrin compounds. The compounds are useful as peroxynitrite decomposition catalysts. Pharmaceutical compositions, and methods of making and using the compounds, or a pharmaceutically acceptable salt, hydrate, or prodrug thereof are also described. | 04-15-2010 |
| 20100173885 | ORGANOMETEALLIC COMPOUNDS - The present invention relates to novel organometallic compounds for use as a medicine, in particular in photodynamic therapy against various diseases, such as cancer or inflammatory and/or immune disorders. The compounds comprise a central porphyrin or phtalocyanine backbone to which ligand linkers coordinated to at least one transition metal are attached. Eta-5 or eta-6 arenes further bind to the transition metal. According to a preferred embodiment, the compound is a tetranuclear Ruthenium (+II) complex. | 07-08-2010 |
| 20100204193 | METAL COMPLEXES INCORPORATED WITHIN BIODEGRADABLE NANOPARTICLES AND THEIR USE - The invention is directed to providing a compound for treating cancer, the compound comprising a metal complex having predetermined characteristics, and which may be incorporated into a polymeric nanoparticle or other delivery system for delivering the metal complex for action on tumor cells. The metal complex for treating cancer wherein the metal complex is a silver(I) salt, a silver(I) macrocyclic metal complex, a silver(I) N-heterocyclic carbene or mixtures thereof. The invention is also directed to a silver(I) macrocyclic metal complex and a silver(I) N-heterocyclic carbine, and methods of treating cancerous cells in a mammal including the steps of administering an effective amount of a silver(I) metal salt, such as by incorporating the material into a biodegradable polymeric nanoparticle. | 08-12-2010 |
| 20110039816 | THERAPEUTIC SUBSTANCE, PHARMACEUTICAL COMPOSITION, HELICOBACTER PYLORI GROWTH INHIBITOR AND METHOD FOR CONDUCTING ANTI-HELICOBACTER THERAPY - The invention belongs to the area of medicine and can be used as a therapeutic substance and as an inhibitor of the growth of | 02-17-2011 |
| 20110046100 | Texaphyrin solutions and pharmaceutical formulations - A packaging system is described for a drug that provides protection from contamination, crystallization and/or degradation of the drug during storage of the system prior to its use. The packaging of the drug does not significantly absorb, react with, or otherwise adversely affect the therapeutic effectiveness of the drug or other excipients or components during storage of the system prior to its use. The packaging system is also used for preserving a drug, particularly a drug containing high-purity texaphyrin metal complexes, by providing a product packaging system that prevents, limits or otherwise controls degradation reactions that can result from exposure to oxygen and/or light. | 02-24-2011 |
| 20110065679 | Substituted Porphyrins - The present invention relates, in general, to a method of modulating physiological and pathological processes and, in particular, to a method of modulating cellular levels of oxidants and thereby processes in which such oxidants are a participant. The invention also relates to compounds and compositions suitable for use in such methods. | 03-17-2011 |
| 20110065680 | Metal Complexes - A method for synthesizing a complex having the formula: [L3MO3]″ wherein L | 03-17-2011 |
| 20110098262 | CORROLES FOR NEUROPROTECTION AND NEURORESCUE - Transition metal complexes of amphiphilic corroles, optical isomers and pharmaceutically acceptable salts thereof are useful for neuroprotection and neurorescue, particularly for treatment of diabetes and neurodegenerative diseases. The amphiphilic corrole is preferably a 5,10,15-tris-aryl- or 5,10,15-tris-CF | 04-28-2011 |
| 20110098263 | HYDROXY-SUBSTITUTED COLD(III) PORPHYRIN COMPLEXES AS HISTONE DEACETYLASE INHIBITORS - A method for treatment of cancer by inhibiting the activity of histone deacetylase, comprising administering to a human in need of such treatment a composition containing a therapeutically effective amount of a gold(III) complex having the structural formula of | 04-28-2011 |
| 20110105452 | Oxidant Scavengers for Treatment of Diabetes or Use in Transplantation or Induction of Immune Tolerance - The present invention relates, in one embodiment, to a method of preventing or treating diabetes using low molecular weight antioxidants. In a further embodiment, the invention relates to a method of protecting and/or enhancing viability of cells/tissues/organs during isolation (harvesting), preservation, expansion and/or transplantation. In yet another embodiment, the present invention relates to a method of inducing immune tolerance. The invention also relates to compounds and compositions suitable for use in such methods. | 05-05-2011 |
| 20110136774 | Anti-Apoptotic Benzodiazepine Receptor Ligand Inhibitors - The present invention provides low molecular weight porphyrin compositions for inhibiting, preventing or delaying the binding of a ligand of a mitochondrial benzodiazepine receptor. The invention also provides pharmaceutical compositions comprising these porphyrin compositions and their use in the treatment of conditions involving the mitochondrial benzodiazepine receptor or interactions between the receptor and the mitochondrial permeability transition pore e.g., drug overdose or apoptosis including neural degeneration and radiation-induced apoptosis. | 06-09-2011 |
| 20110136775 | Methods for Treating Injury Associated with Exposure to an Alkylating Species - Compounds may be administered to prevent or rescue organ injury following exposure to alkylating agents, such as sulfur mustards. The compounds may be substituted metalloporphyrins. | 06-09-2011 |
| 20110144078 | TRANSITION METAL COMPLEXES OF CORROLES FOR PREVENTING CARDIOVASCULAR DISEASES OR DISORDERS - Transition metal complexes of amphiphilic/bipolar corroles, optically active isomers or pharmaceutically acceptable salts thereof are useful for prevention of a cardiovascular disease or disorder in a subject susceptible to develop such a cardiovascular disease or disorder. | 06-16-2011 |
| 20110275606 | SUBSTITUTED PORPHYRINS - Discloses are compounds according to Formula I. Further provided are methods of reducing oxidative stress in a cell, methods of treating a disease including cancer, and methods of treating a subject with a disorder associated with oxidative stress, the methods including administering a compound according to the invention. Also disclosed are methods of potentiating a cancer cell for treatment with ionizing radiation or chemotherapeutics including contacting the cell with an effective amount of a compound according to the invention. Further discloses are pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a compound according to the invention. | 11-10-2011 |
| 20110306584 | Porphyrin Catalysts and Methods of Use Thereof - This invention provides a novel class of substituted macrocyclic metallic compounds. The compounds are useful as peroxynitrite decomposition catalysts. Pharmaceutical compositions, and methods of making and using the compounds, or a pharmaceutically acceptable salt, hydrate, or prodrug thereof are also described. | 12-15-2011 |
| 20120065181 | METHOD OF PROVIDING NEUROPROTECTION USING SUBSTITUTED PORPHYRINS - Described herein are methods of treating ischemic injury comprising administering to a subject in need thereof a therapeutically effective amount of a substituted porphyrin compound. Also disclosed are methods of providing neuroprotection, methods of treating subarachnoid hemorrhage, methods of treating traumatic brain injury and methods of treating spinal cord injury using substituted porphyrins. | 03-15-2012 |
| 20120135972 | PHTHALOCYANINE DERIVATIVE CONSISTING OF A MIXTURE OF 4 ISOMERS - There is described a phthalocyanine derivative of formula (I) consisting of 4 isomers wherein the relative isomer B content is less than or equal to 1% by weight. | 05-31-2012 |
| 20120142658 | THERAPEUTICAL USE OF TERNARY COMPLEXES OF VALPROIC ACID - A method of treating a human subject having a condition responsive to valproic acid therapy, includes administering to the subject an effective amount of a metal-based ternary complex of valproic acid with nitrogen donor ligands, in particular with diimines or diamines. | 06-07-2012 |
| 20120214780 | SUBSTITUTED PORPHYRINS - The present invention relates, in general, to a method of modulating physiological and pathological processes and, in particular, to a method of modulating cellular levels of oxidants and thereby processes in which such oxidants are a participant. The invention also relates to compounds and compositions suitable for use in such methods. | 08-23-2012 |
| 20120264724 | ANTIMICROBIAL AGENTS BASED ON HEMIN DERIVATIVES - The invention relates to novel antimicrobial, including antibacterial and antifungal, agents and compositions based on hemin derivatives of general formula (I), and also to the production of novel hemin derivatives. The advantages of antibacterial agents based on hemin derivatives are their biocompatibility, biodegradability, high effectiveness against resistant bacteria and widespread microfungi that are harmful to humans, and freedom from toxicity and side effects. | 10-18-2012 |
| 20120264725 | SUBSTITUTED PORPHYRINS - Substituted metalloporphyrin compounds are described, along with pharmaceutical compositions containing the same, and methods of use thereof in protecting cells from oxidant-induced toxicity and pathological conditions such as inflammatory lung disease, neurodegenerative conditions, radiation injury, cancer, diabetes, cardiac conditions and sickle cell disease. Mn(III) porphyrins bearing oxygen atoms within side chains are particularly described. | 10-18-2012 |
| 20120283235 | Dermatologic and Cosmetic Compositions - Provided are compositions and methods for treatment of conditions and diseases of the skin, for example fine lines and wrinkles and rosacea. The compositions include a porphyrin that is a chlorophyllin, a chlorin compound, a complex of a chlorin compound, or a salt or ester of the chlorin compound or its complex. | 11-08-2012 |
| 20120283236 | Porphyrin Catalysts and Methods of Use Thereof - This invention provides a novel class of substituted macrocyclic porphyrin compounds. The compounds are useful as peroxynitrite decomposition catalysts. Pharmaceutical compositions, and methods of making and using the compounds, or a pharmaceutically acceptable salt, hydrate, or prodrug thereof are also described. | 11-08-2012 |
| 20120289492 | METHODS OF TREATING MITOCHONDRIAL DISORDERS USING METALLOPORPHYRINS - Methods of treating a mitochondrial disorder including epilepsy, a neurological disorder, an inherited mitochondrial disease or inherited epilepsies, a pediatric epilepsy, an encephalopathy or a pediatric movement disorder are provided, as well as compounds useful in the methods of the invention, such as metalloporphyrin compounds as disclosed herein. | 11-15-2012 |
| 20120295880 | Compounds With Modifying Activity Enhanced Under Hypoxic Conditions - Compositions and methods for modifying one or more biologic targets are provided. Suitable targets include cells, DNA, proteins, enzymes, and/or a subject in need thereof. The compositions may exist as a monomer or multimer and are active in a biologic environment with enhanced activity in hypoxic environments and, thus, exhibit improved specificity for hypoxic biologic targets (e.g., tumorigenic cells and those undergoing uncontrolled cell growth). A composition typically comprises a complex with an overall charge of 2+ or greater having at least one ruthenium atom attached to a redox active ligand. The redox active ligand helps maintain separation of more than one ruthenium atom. Suitable compositions may further include a terminal ligand comprising a heterocyclic aromatic compound. When provided to a biologic target, the composition modifies the biologic target and no additional compounds need be provided. Suitable compositions are typically catalytic and regenerative in the presence of a reducing agent. | 11-22-2012 |
| 20120329767 | Methods and Compositions for Treating Cancer - The present invention relates to uses or methods for treating proliferative diseases, in particular cancer, implementing ruthenium compounds, as well as to composition containing same. | 12-27-2012 |
| 20130029959 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER - The present invention relates to compositions, kits, and methods for treatment of cancers. In some cases, the composition comprises a platinum compound comprising a phenanthridine ligand. | 01-31-2013 |
| 20130090319 | METALLOINSERTOR COMPLEXES TARGETED TO DNA MISMATCHES - A composition including a Rh or Ru metalloinsertor complex specifically targets mismatch repair (MMR)-deficient cells. Selective cytotoxicity is induced in MMR-deficient cells upon uptake of the inventive metalloinsertor complexes. | 04-11-2013 |
| 20130123228 | PROMOTING AXON REGENERATION IN THE ADULT CNS THROUGH CONTROL OF PROTEIN TRANSLATION - Survival of, or axon regeneration in a lesioned mature central nervous system (CNS) neuron is promoted by (a) contacting the neuron with a therapeutically effective amount of an exogenous activator of protein translation; and (b) detecting the resultant promotion of the survival of, or axon regeneration in the neuron. | 05-16-2013 |
| 20130157994 | HIGH-PURITY TEXAPHYRIN METAL COMPLEXES - Disclosed herein are the methods and compositions for the improved synthesis of texaphyrin metal complexes. The improved synthesis results in high-purity compositions of texaphyrin metal complexes in which more than about 98% of the texaphyrin metal complexes in the composition have the same structure and/or the same molecular weight. Further described herein are pharmaceutical compositions comprising such high-purity compositions, and the use of such high-purity compositions in the treatment of cancer and cardiovascular diseases and disorders. | 06-20-2013 |
| 20130225545 | PORPHYRIN TREATMENT OF NEURODEGENERATIVE DISEASES - Compositions and methods of treating a neurodegenerative disorder are disclosed herein. | 08-29-2013 |
| 20130261098 | ORGANIC ELECTROLUMINESCENT DEVICE - The present invention relates to compounds of the general formula (S-A)n-T, in which at least one fluorescent group S is linked to a phosphorescent group T via a divalent group A, to the use thereof in an electronic device, and to a formula to a formulation and an electronic device which comprise the novel compounds. | 10-03-2013 |
| 20130324511 | PHARMACEUTICAL COMPOSITION CONTAINING CYCLOMETALATED N-HETEROCYCLIC CARBENE COMPLEXES FOR CANCER TREATMENT - The present disclosure is related to a pharmaceutical composition for treatment of cancer comprising a cyclometalated N-heterocyclic carbene complex. The cyclometalated N-heterocyclic carbene complex contains a gold(III) or a platinum(II) atom. The pharmaceutical composition possesses anti-cancer activity such as the induction of cell death, inhibition of cellular proliferation, inhibition of topoisomerase and/or poisoning of topoisomerase. | 12-05-2013 |
| 20130331367 | METAL-BASED THIOPHENE PHOTODYNAMIC COMPOUNDS AND THEIR USE - Compositions of the invention include tunable metal-based thiophene photodynamic compounds useful as therapeutic agents and as in vivo diagnostic agents for treating or preventing diseases that involve hyperproliferating cell etiology including cancer and diseases associated with hyperproliferating cells. The compositions are also useful for treating infectious diseases and for pathogen disinfection. | 12-12-2013 |
| 20130345189 | METALLOINSERTOR COMPLEXES TARGETED TO DNA MISMATCHES - A composition including a Rh or Ru metalloinsertor complex specifically targets mismatch repair (MMR)-deficient cells. Selective cytotoxicity is induced in MMR-deficient cells upon uptake of the inventive metalloinsertor complexes. | 12-26-2013 |
| 20140045810 | METAL COMPLEXES - The present invention relates to metal complexes and to electronic devices, in particular organic electroluminescent devices, comprising these metal complexes. | 02-13-2014 |
| 20140073619 | METHOD FOR TREATING CHRONIC PAIN - The present invention provides analgesic compounds comprising at least one modified metalloporphyrin compound. Also provided are methods of treating pain by orally administering an analgesic compounds comprising at least one modified metalloporphyrin compound. | 03-13-2014 |
| 20140121191 | Oral Energy Supplement and Related Methods - The present invention relates to oral dosage formulations consisting of at least one active ingredient contained in a plurality of hydrophobic carriers dispersed in an aqueous medium comprising a hydrocolloid. The active ingredients include various energy supplements, such as caffeine and vitamins. The formulations may further include emulsifiers, permeation enhancers, and vasodilators. The invention further relates to methods of making the oral dosage formulations. | 05-01-2014 |
| 20140343028 | METHODS OF TREATING ORAL MUCOSITIS - Methods and kits for treating oral mucositis are disclosed. The treatment comprises administering to a patient in need thereof a Reactive Oxygen Species scavenger in a pharmaceutically acceptable formulation. | 11-20-2014 |
| 20140357610 | COMPOSITION AND METHOD FOR AFFECTING OBESITY AND RELATED CONDITIONS - A method of reducing caloric intake or food intake in a mammal in need thereof. The method including delivering an effective amount of a compound comprising manganese [III] tetrakis (4-benzoic acid) porphyrin (MnTBAP) or analogs thereof to a mammal over a period of time sufficient to induce a reduction in caloric intake or food intake of the mammal. | 12-04-2014 |
| 20140364406 | Method Of Treating Or Preventing Pathologic Effects Of Acute Increases In Hyperglycemia And/Or Acute Increases Of Free Fatty Acid Flux - One aspect of the present invention relates to a method of treating or preventing pathologic sequelae of acute hyperglycemia and/or increased fatty acid flux in a subject. This method involves administering an ROS inhibitor to the subject. In addition, methods of promoting neovascularization, inhibiting oxidation or excessive release of free fatty acids, and identifying compounds suitable for treatment or prevention of ROS-mediated injury are also disclosed. | 12-11-2014 |
| 20140371192 | ALPHA-FORM ZINC-PHTHALOCYANINE NANOWIRES HAVING ENHANCED WATER SOLUBILITY AND WATER DISPERSIBILITY, COMPOSITE OF AN ALPHA-FORM ZINC-PHTHALOCYANINE NANOWIRE/PHENOTHIAZINE, AND METHOD FOR PREPARING SAME - The present invention relates to alpha-form zinc-phthalocyanine nanowires (ZnPc NWs) having enhanced water solubility and water dispersibility, to a composite of an alpha-form zinc-phthalocyanine nanowire/phenothiazine, to a method for preparing same, and to a photosensitizer including same or a pharmaceutical composition including same for preventing or treating cancers. Since the alpha-form zinc-phthalocyanine nanowires or the composite of alpha-form zinc-phthalocyanine nanowire/phenothiazine according to the present invention exhibit dual traits, i.e., photothermal and photodynamic traits in single molecules, they are very useful for the development of a multifunctional molecular system and can also be usefully applied to light therapy of cancers due to their good light therapeutic effects. Also, the composite of alpha-form zinc-phthalocyanine nanowire/phenothiazine itself can exhibit fluorescence to facilitate the introduction of an imaging system, so that diagnosis and treatment can be simultaneously performed using a single substance. | 12-18-2014 |
| 20140378427 | CABAZITAXEL-PLATINUM NANOPARTICLES AND METHODS OF USING SAME - The present teachings relate to compounds and compositions for treatment of cancers. In some embodiments, the composition comprises a platinum compound having a heterocycle ligand. Cabazitaxel-platinum nanoparticles are disclosed herein, as well as methods of making and using the same. | 12-25-2014 |
| 20150290214 | METHOD OF TREATMENT OF DISEASE - An embodiment of the invention provides a use of an effective amount of a transition metal complex of a corrole, an optically active isomer thereof, or a pharmaceutically acceptable salt thereof for treating a disease of the eye and/or the kidney in a subject suffering from diabetes. An embodiment of the invention further provides a use of a transition metal complex of a corrole, an optically active isomer thereof, or a pharmaceutically acceptable salt thereof for lowering serum glucose and serum triglyceride levels in a subject suffering from diabetes. | 10-15-2015 |
| 20150299233 | COMPOSITIONS AND METHODS COMPRISING RHENIUM FOR THE TREATMENT OF CANCERS - Compositions and methods comprising rhenium are provided. In some embodiments, the rhenium compounds comprise a bidentate ligand. In some embodiments, the rhenium compounds are used in method for treating cancer. | 10-22-2015 |
| 20150353590 | METHODS AND COMPOSITIONS FOR TREATMENT OF CYANIDE AND HYDROGEN SULFIDE TOXICITY - A composition and method for treating excess cyanide and hydrogen sulfide comprising administering a cobinamide. Further a method for determining extent of binding by an agent to an extracellular matrix. | 12-10-2015 |
| 20160000802 | HIGH-PURITY LARGE-SCALE PREPARATION OF STANNSOPORFIN - Large scale (bulk) compositions comprising high-purity stannsoporfin are disclosed, as well as methods of synthesizing such compositions. | 01-07-2016 |
| 20160008468 | DISEASE DETECTION AND TREATMENT THROUGH ACTIVATION OF COMPOUNDS USING EXTERNAL ENERGY | 01-14-2016 |
| 20160051676 | TRANSITION METAL PORPHYRIN COMPLEXES AND METHODS OF TREATMENT USING SAME - A porphyrin of general formula (I) having a transition metal (II) cation in its core and one or two mono-, di-, tri-, tetra- or penta-halophenyl groups and two or three pyridyl groups in the 5, 10, and/or 15 positions of the porphyrin ring contributing to a positive two or three charge neutralized by the presence of a respective number of anions. The porphyrin of the general formula (I) characterized by killing | 02-25-2016 |
| 20160151383 | METHODS FOR TREATMENT OF DISEASES | 06-02-2016 |
| 20160166582 | PROTEASOME INHIBITORS AND USES THEREOF | 06-16-2016 |
| 20160166705 | THERAPEUTICAL USE OF TERNARY COMPLEXES OF VALPROIC ACID | 06-16-2016 |
| 20170231903 | NANOPARTICLES FOR PHOTODYNAMIC THERAPY, X-RAY INDUCED PHOTODYNAMIC THERAPY, RADIOTHERAPY, CHEMOTHERAPY, IMMUNOTHERAPY, AND ANY COMBINATION THEREOF | 08-17-2017 |
| 20170233423 | PT (IV) Complexes Containing 4,4'-Disubstituted-2,2'-Bipyridyl and Their Use in Cancer Therapy | 08-17-2017 |
| 20190142955 | PHARMACEUTICAL COMPOSITION CONTAINING MACROMOLECULAR DRUG | 05-16-2019 |
